KR102465347B1 - A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem - Google Patents
A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem Download PDFInfo
- Publication number
- KR102465347B1 KR102465347B1 KR1020200129598A KR20200129598A KR102465347B1 KR 102465347 B1 KR102465347 B1 KR 102465347B1 KR 1020200129598 A KR1020200129598 A KR 1020200129598A KR 20200129598 A KR20200129598 A KR 20200129598A KR 102465347 B1 KR102465347 B1 KR 102465347B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- gujeolcho
- peppermint
- inflammatory
- lemongrass
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 230000000694 effects Effects 0.000 title description 10
- 206010061218 Inflammation Diseases 0.000 title description 6
- 241001331134 Chrysanthemum zawadskii Species 0.000 title description 3
- 235000018947 Chrysanthemum zawadskii Nutrition 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 135
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 50
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 230000014509 gene expression Effects 0.000 claims description 12
- 102000004889 Interleukin-6 Human genes 0.000 claims description 10
- 108090001005 Interleukin-6 Proteins 0.000 claims description 10
- 235000020737 peppermint extract Nutrition 0.000 claims description 3
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 claims 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 claims 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims 1
- 240000004784 Cymbopogon citratus Species 0.000 abstract description 45
- 235000017897 Cymbopogon citratus Nutrition 0.000 abstract description 45
- 235000004357 Mentha x piperita Nutrition 0.000 abstract description 41
- 244000246386 Mentha pulegium Species 0.000 abstract description 40
- 235000016257 Mentha pulegium Nutrition 0.000 abstract description 40
- 235000001050 hortel pimenta Nutrition 0.000 abstract description 40
- 241000675108 Citrus tangerina Species 0.000 abstract description 38
- 235000013305 food Nutrition 0.000 description 27
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 14
- 241000332371 Abutilon x hybridum Species 0.000 description 13
- 230000036541 health Effects 0.000 description 13
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 12
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 11
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 11
- 235000014443 Pyrus communis Nutrition 0.000 description 10
- 240000001987 Pyrus communis Species 0.000 description 10
- 238000009472 formulation Methods 0.000 description 9
- 229940100601 interleukin-6 Drugs 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 235000013376 functional food Nutrition 0.000 description 8
- 241000234314 Zingiber Species 0.000 description 7
- 235000006886 Zingiber officinale Nutrition 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 235000006708 antioxidants Nutrition 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 235000008397 ginger Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- -1 aromatics Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 238000010269 ABTS assay Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 239000002562 thickening agent Substances 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000004278 EU approved seasoning Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000011194 food seasoning agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZKQDCIXGCQPQNV-UHFFFAOYSA-N Calcium hypochlorite Chemical compound [Ca+2].Cl[O-].Cl[O-] ZKQDCIXGCQPQNV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 244000173610 Mentha aquatica Species 0.000 description 2
- 235000012629 Mentha aquatica Nutrition 0.000 description 2
- 235000014749 Mentha crispa Nutrition 0.000 description 2
- 241001093501 Rutaceae Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000021109 kimchi Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 231100000544 menstrual irregularity Toxicity 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000001256 tonic effect Effects 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GGLIEWRLXDLBBF-UHFFFAOYSA-N Dulcin Chemical compound CCOC1=CC=C(NC(N)=O)C=C1 GGLIEWRLXDLBBF-UHFFFAOYSA-N 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 206010016326 Feeling cold Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000021710 Hyperpigmentation disease Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000007421 Mentha citrata Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 244000078639 Mentha spicata Species 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000878007 Miscanthus Species 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 241001310492 Pectis angustifolia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- WINXNKPZLFISPD-UHFFFAOYSA-M Saccharin sodium Chemical compound [Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 WINXNKPZLFISPD-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 235000013527 bean curd Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000002026 carminative effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008126 dulcin Substances 0.000 description 1
- NWNUTSZTAUGIGA-UHFFFAOYSA-N dulcin Natural products C12CC(C)(C)CCC2(C(=O)OC2C(C(O)C(O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(O)CC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1OC1OC(CO)C(O)C(O)C1O NWNUTSZTAUGIGA-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 241001233957 eudicotyledons Species 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 235000019985 fermented beverage Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 235000015092 herbal tea Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 239000001220 mentha spicata Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- LPUQAYUQRXPFSQ-DFWYDOINSA-M monosodium L-glutamate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCC(O)=O LPUQAYUQRXPFSQ-DFWYDOINSA-M 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001432 poly(L-lactide) Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940086065 potassium hydrogentartrate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000020991 processed meat Nutrition 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 복합 추출물에 관한 것으로, 구체적으로, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 조성물에 관한 것이다.
본 발명의 구절초 잎줄기, 페퍼민트, 레몬그라스, 귤피 추출물을 단독으로 처리할 경우에는 염증 억제 효능이 나타나지 않았으나, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 복합하여 처리할 경우, 염증 억제 효능이 나타난 것을 확인하였기에, 상기 추출물 조합은 항염증용 조성물로서 널리 활용될 수 있을 것이다.The present invention (i) gujeolcho extract; And (ii) relates to a complex extract comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract, specifically, (i) Gujeolcho extract; and (ii) an anti-inflammatory composition comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extracts.
When the extracts of gujeolcho leaf stem, peppermint, lemongrass, and tangerine peel of the present invention were treated alone, the anti-inflammatory effect was not shown, but (i) gujeolcho extract; And (ii) when one extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract was treated in combination, it was confirmed that the anti-inflammatory effect was exhibited, so that the extract combination can be widely used as an anti-inflammatory composition. There will be.
Description
본 발명은 (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 복합 추출물에 관한 것으로, 구체적으로, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 조성물에 관한 것이다.The present invention (i) gujeolcho extract; And (ii) relates to a complex extract comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract, specifically, (i) Gujeolcho extract; and (ii) an anti-inflammatory composition comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extracts.
현대에는 경제발전과 더불어 식생활의 형태가 급변하고 평균수명 연장에 따른 인구의 고령화와 질병의 많은 변화로 웰빙 바람과 함께 건강에 대한 관심이 어느 때보다 높아짐에 따라, 천연물을 기원으로 하는 생약을 한방에서의 질병 치료제나 보약 처방으로 널리 사용하여 왔으나 최근 들어서는 예방의학적 차원에서 건강과 영양까지 고려한 각종 기능성 식품 등의 소재로 다양하게 개발하고 있다.In modern times, as interest in health has increased more than ever with the well-being trend due to rapid changes in the form of eating habits along with economic development, aging of the population and many changes in diseases due to the extension of average life span, herbal medicines derived from natural products have been developed. It has been widely used as a disease treatment or supplement prescription, but recently, it is being developed as a material for various functional foods considering health and nutrition in terms of preventive medicine.
구절초(Chrysanthemum zawadskii)는 국화과에 속하는 다년생 쌍떡잎식물로, 구절초는 전국 각처의 산지와 고원지에서 자생하고 중국, 러시아, 몽골, 일본 등지에서 자란다고 알려져 있다. 구절초는 그 줄기와 잎을 말려 예로부터 월경불순, 자궁냉증, 불임증의 부인병과 위장병 등에 효능을 가지는 생약으로 사용되고 있다.Gujeolcho (Chrysanthemum zawadskii) is a perennial dicotyledon belonging to the Asteraceae family. Gujeolcho is known to grow naturally in mountains and highlands throughout the country and to grow in China, Russia, Mongolia, and Japan. Dried stems and leaves of Gujeolcho have been used since ancient times as herbal medicines that are effective for menstrual irregularities, cold uterus, infertility, and gynecological and gastrointestinal diseases.
한편, 인체 내에서 대식세포는 병원체에 반응하여 종양 괴사 인자-α(tumor necrotic factor-α, TNF-α), 인터루킨-6(IL-6), 인터루킨-1β(IL-1β) 등과 같은 염증유발인자를 생성하고, 유도성 일산화질소 합성효소(inducible nitric oxide synthase, iNOS)와 사이클로옥시게나제-2(cyclooxygenase-2, COX-2)를 합성하여 일산화질소(NO) 및 프로스타글란딘(prostaglandin E2, PGE2)을 생성한다. 생리학적으로 NO는 세균과 종양을 제거하고 혈압을 조절하거나 신경 전달을 매개하는 등 다양한 역할을 한다. 그러나 염증 반응이 일어나게 되면 관련 세포들에서 iNOS의 발현이 증가하여 많은 양의 NO가 생성되고, 과도하게 생성된 NO는 조직의 손상, 유전자 변이, 신경 손상 등을 유발하며, 혈관 투과성을 증가시켜 부종 등의 염증 반응을 촉진시킨다. 이러한 염증 반응을 줄이기 위해 새로운 항염증 물질에 대한 다양한 연구가 이루어지고 있다.Meanwhile, macrophages in the human body respond to pathogens and induce inflammation such as tumor necrotic factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β). factor, and synthesizes inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) to generate nitric oxide (NO) and prostaglandin (prostaglandin E2, PGE2). ) to create Physiologically, NO plays a variety of roles, including eliminating bacteria and tumors, regulating blood pressure, and mediating nerve transmission. However, when an inflammatory reaction occurs, the expression of iNOS in related cells increases and a large amount of NO is produced. Excessive production of NO causes tissue damage, genetic mutation, nerve damage, etc. promotes the inflammatory response. In order to reduce this inflammatory reaction, various studies on new anti-inflammatory substances are being conducted.
일 예로, 국내등록특허 10-2132655에서는 구절초 추출물을 포함하는 조성물의 항산화 효능에 관하여 개시하고 있고, 국내등록특허 10-2045903에서는 구절초 추출물을 포함하는 월경전 증후군 개선용 조성물에 관하여 개시하고 있으나, 구절초 잎줄기 추출물과 페퍼민트, 레몬그라스, 또는 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 복합 추출물의 항염증 효능에 관하여는 밝혀진 바 없으며, 본 발명자에 의하여 최초로 규명되었다.For example, Korean Patent No. 10-2132655 discloses the antioxidant efficacy of a composition containing an extract of Gujeolcho, and Korean Patent No. 10-2045903 discloses a composition for improving premenstrual syndrome containing an extract of Gujeolcho. The anti-inflammatory efficacy of a complex extract containing, as an active ingredient, an extract selected from the group consisting of a leaf stem extract and peppermint, lemongrass, or tangerine peel extract has not been identified, and was identified for the first time by the present inventors.
이러한 배경 하에, 본 발명자들은 새로운 항염증 효능을 가지는 천연물 유래 소재를 개발하고자 예의 연구 노력한 결과, 구절초 잎줄기 추출물과 페퍼민트, 레몬그라스, 또는 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 복합 추출물에서 단독 추출물에서는 나타나지 않았던 항염증 효능을 확인하여, 본 발명을 완성하였다.Under this background, the present inventors have made diligent research efforts to develop a natural product-derived material having new anti-inflammatory efficacy. The present invention was completed by confirming the anti-inflammatory effect that was not shown in the single extract in the composite extract containing the extract.
본 발명의 하나의 목적은 구절초 잎줄기 추출물과 페퍼민트, 레몬그라스, 또는 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 조성물을 제공하는 것이다.One object of the present invention is to provide an anti-inflammatory composition comprising an extract selected from the group consisting of gujeolcho leaf stem extract and peppermint, lemongrass, or tangerine peel extract as an active ingredient.
이를 구체적으로 설명하면 다음과 같다. 한편, 본 발명에서 개시된 각각의 설명 및 실시형태는 각각의 다른 설명 및 실시 형태에도 적용될 수 있다. 즉, 본 발명에서 개시된 다양한 요소들의 모든 조합이 본 발명의 범주에 속한다. 또한, 하기 기술된 구체적인 서술에 의하여 본 발명의 범주가 제한된다고 볼 수 없다.A detailed description of this is as follows. Meanwhile, each description and embodiment disclosed in the present invention may also be applied to each other description and embodiment. That is, all combinations of the various elements disclosed herein fall within the scope of the present invention. In addition, it cannot be seen that the scope of the present invention is limited by the specific descriptions described below.
상기 목적을 달성하기 위한 본 발명의 하나의 양태는, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 조성물을 제공한다.One aspect of the present invention for achieving the above object, (i) gujeolcho extract; and (ii) an anti-inflammatory composition comprising an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract as an active ingredient.
구체적으로, 상기 추출물은 열수 추출물일 수 있으며, 바람직하게, 상기 구절초 추출물은 구절초 잎과 줄기의 추출물(잎줄기 추출물)인 것일 수 있다. 보다 구체적으로, 상기 귤피 추출물은 구절초 잎줄기 추출물과 1:0.5 내지 1:1.5의 비율로 포함되고, 상기 페퍼민트 추출물은 구절초 잎줄기 추출물과 5:1 내지 15:1의 비율로 포함되고, 상기 레몬그라스 추출물은 구절초 잎줄기 추출물과 5:1 내지 15:1의 비율로 포함되는 것 일 수 있으나, 이에 제한되는 것은 아니다.Specifically, the extract may be a hot water extract, and preferably, the gujeolcho extract may be an extract of gujeolcho leaves and stems (leaf stem extract). More specifically, the tangerine peel extract and the Gujeolcho leaf stem extract are included in a ratio of 1:0.5 to 1:1.5, the peppermint extract is included in the Gujeolcho leaf stem extract and the ratio of 5:1 to 15:1, and the lemon Grass extract may be included in the ratio of gujeolcho leaf stem extract and 5: 1 to 15: 1, but is not limited thereto.
또한, 상기 항염증 효능은 iNOS, COX-2, 또는 IL-6 발현 감소능에 의해 이루어지는 것일 수 있으나, 이에 제한되는 것은 아니다.In addition, the anti-inflammatory effect may be achieved by reducing the expression of iNOS, COX-2, or IL-6, but is not limited thereto.
본 발명에서의 용어, “구절초(Chrysanthemum zawadskii)”는 국화과에 속하는 여러해살이풀로서, 우리나라 전역에 야생하고 있으며 동속으로는 바위구절초, 산구절초, 포천구절초, 및 서홍 구절초 등이 있다. 민간에서는 주로 부인병의 냉증, 월경통, 월경불순 등에 치료효과가 있는 것으로 사용되어져 왔으나 구절초 추출물의 항염증 효능에 대하여는 본 발명자에 의해 최초로 규명되었다.The term "Chrysanthemum zawadskii" in the present invention is a perennial plant belonging to the Asteraceae family, and is wild throughout Korea, and includes Rock Gujeolcho, Sangujeolcho, Pocheon Gujeolcho, and Seohong Gujeolcho. In the private sector, it has been mainly used as a treatment for women's diseases such as coldness, dysmenorrhea, menstrual irregularity, etc., but the anti-inflammatory efficacy of Gujeolcho extract was first identified by the present inventors.
본 발명에 있어서, 상기 구절초 추출물의 항염증 효능을 위하여 바람직하게는 구절초의 생화 또는 건화를 사용한 것일 수 있다.In the present invention, for the anti-inflammatory effect of the extract of gujeolcho, preferably fresh or dried gujeolcho may be used.
본 발명에서의 용어, “페퍼민트(Mentha piperita)는 물 민트(water mint; Mentha aquatica)와 스피어민트(spearmint; Mentha spicata)가 교배된 민트로서, 식물 전체에 존재하는 휘발성 기름 때문에 매우 특징적인 향기가 난다. 페퍼민트의 오일은 동서양에서 전통적으로 암, 감기, 경련, 소화 불량 또는 치통 등의 치료에 사용되며 방향제 내지 방부제로도 사용되었다.The term in the present invention, “Peppermint (Mentha piperita) is a mint that is a hybrid of water mint (Mentha aquatica) and spearmint (Mentha spicata), and has a very characteristic fragrance due to volatile oil present throughout the plant. . Peppermint oil is traditionally used in the East and West to treat cancer, colds, convulsions, indigestion or toothache, and has also been used as an aromatic or antiseptic.
반면, 구절초 및 페퍼민트를 유효성분으로 포함하는 복합 추출물의 항염증 효능에 대하여는 본 발명자에 의해 최초로 확인되었다.On the other hand, the anti-inflammatory efficacy of the composite extract containing gujeolcho and peppermint as active ingredients was first confirmed by the present inventors.
본 발명에서의 용어, “레몬그라스(Lemongrass)”는 화본과로(학명: Cymbopogon Citratus) 인도, 아시아, 아프리카, 중남미의 열대지역이 원산지로 다년생 초목으로 잎을 비비면 레몬향이 난다고 해서 붙여진 이름이다. 레몬그라스는 8 ~ 9월경에 잎 사이에서 가느다란 원추화서가 나와 많은 이삭을 내는데 억새와 비슷한 모양을 한다. 주산지는 과테말라, 브라질, 마다카스카르 등에서 대량으로 재배하고 있다. 레몬그라스 향료는 화장품, 비누, 캔디, 의약품 등에 향료로 사용하며 잎은 식재료 뿐만 아니라 허브차로도 마신다. 또한, 강장, 진통, 항진균, 유즙분비, 소화기계 강장, 데오드란트, 방충 등에 효능이 있는 것으로 알려져 있다.The term "Lemongrass" in the present invention is a herbaceous plant (scientific name: Cymbopogon Citratus) native to the tropical regions of India, Asia, Africa, and Central and South America. It is a perennial plant that has a lemon scent when rubbed. Lemongrass produces thin panicles between the leaves around August and September and produces many ears, which look similar to silver grass. It is cultivated in large quantities in Guatemala, Brazil, and Madagascar. Lemongrass fragrance is used as a fragrance for cosmetics, soaps, candies, medicines, etc., and the leaves are drunk not only as ingredients but also as herbal tea. In addition, it is known to be effective in tonic, pain relief, antifungal, lactation, digestive system tonic, deodorant, and insect repellent.
반면, 구절초 및 레몬그라스를 유효성분으로 포함하는 복합 추출물의 항염증 효능에 대하여는 본 발명자에 의해 최초로 확인되었다.On the other hand, the anti-inflammatory efficacy of the composite extract containing gujeolcho and lemongrass as active ingredients was first confirmed by the present inventors.
본 발명에서의 용어, “귤피(Citri unshiu Pericarpium)” 추출물은 귤나무 Citrus unshiu Marcorvich 또는 기타 동속식물(운향과 Rutaceae)의 성숙한 과피를 사용하는 것을 의미한다. 이는 건위 구풍작용을 나타내어 소화불량증에 널리 사용된다고 알려져 있다.In the present invention, the term "Citri unshiu Pericarpium" extract means using the mature rind of Citrus unshiu Marcorvich or other plants of the same species (Rutaceae and Rutaceae). It is known to be widely used for dyspepsia because it exhibits a carminative effect on the stomach.
반면, 구절초 및 귤피를 유효성분으로 포함하는 복합 추출물의 항염증 효능에 대하여는 본 발명자에 의해 최초로 확인되었다.On the other hand, the anti-inflammatory efficacy of the complex extract containing gujeolcho and tangerine peel as active ingredients was confirmed by the present inventors for the first time.
본 발명에서의 용어, “복합 추출물”은 두 가지 이상의 추출물이 하나로 합쳐진 추출물을 의미한다.As used herein, the term "complex extract" refers to an extract in which two or more extracts are combined into one.
본 발명에 있어서, 상기 추출물은 구절초 잎줄기 추출물과 페퍼민트, 레몬그라스, 또는 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 하나로 합친 것일 수 있으며, 또는, 상기 구절초 잎줄기 및 페퍼민트, 레몬그라스, 또는 귤피로 구성되는 군에서 선택된 하나를 혼합한 뒤, 추출한 것일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the extract may be a combination of one extract selected from the group consisting of gujeolcho leaf stem extract and peppermint, lemongrass, or tangerine peel extract, or, the gujeolcho leaf stem and peppermint, lemongrass, or It may be extracted after mixing one selected from the group consisting of tangerine peels, but is not limited thereto.
본 발명에서의 용어, “추출물”은 어떤 물질을 추출 처리하여 얻어지는 물질을 의미하는 것으로, 구체적으로 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나, 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.As used herein, the term "extract" refers to a material obtained by extracting a certain substance, and specifically, an extract obtained by extraction, a dilution or concentrate of the extract, a dried product obtained by drying the extract, and the extract. It includes extracts of all formulations that can be formed using the extract itself and the extract, such as a crude product, a purified product, or a mixture thereof.
상기 추출 방법은 특별히 제한되지 않으며, 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 용매 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.The extraction method is not particularly limited, and may be extracted according to a method commonly used in the art. Non-limiting examples of the extraction method include solvent extraction, ultrasonic extraction, filtration, and reflux extraction, which may be performed alone or in combination with two or more methods.
본 발명에서 추출에 사용되는 추출용매의 종류는 특별히 제한되지 않으며, 당해 기술 분야에서 공지된 임의의 용매를 사용할 수 있다. 상기 추출용매의 비제한적인 예로는 물, 탄소수 1 내지 4의 알코올 또는 이들의 혼합 용매 등을 들 수 있으며, 이들은 단독으로 사용되거나 1종 이상 혼합하여 사용될 수 있다. 구체적으로, 상기 추출용매는 열수일 수 있다.The type of extraction solvent used for extraction in the present invention is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the extraction solvent include water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, which may be used alone or in combination of one or more. Specifically, the extraction solvent may be hot water.
본 발명에서의 용어, “유효성분”은 단독으로 목적으로 하는 활성을 나타내거나 또는 그 자체는 활성이 없는 담체 등과 함께 목적으로 하는 활성을 나타낼 수 있는 성분을 의미한다.As used herein, the term “active ingredient” refers to a component capable of exhibiting the desired activity alone or together with a carrier having no activity itself.
본 발명에서의 용어, “항염증”은 염증을 억제하는 작용을 의미하는 것으로, 염증 반응의 조절은 대단히 복잡한 것으로 알려져 있는데, 이는 생체 내 복구체계의 증강 및 손상을 감소시키기 위한 것으로 알려져 있다. 그러나 반복되는 조직의 손상이나 재생에 의해 염증반응이 지속되면, 염증관련 세포에서 ROS와 RNS가 과다 생성되고 그 결과로 영구적인 유전자의 변형이 야기된다. 이처럼 ROS와 RNS는 생체 내 여러 가지 세포의 작용을 조절하는 염증 반응과 깊이 관련되어 있다. 염증 과정 중에는 많은 양의 염증유도 사이토카인(proinflammatory cytokines), 아질산(nitric oxide, NO) 그리고 프로스타글란딘(prostaglandin E2, PGE2)이 유도성 일산화질소 합성효소(inducible nitric oxide synthase, iNOS)와 사이클로옥시게나아제(cyclooxygenase-2, COX-2)에 의해 생성된다.In the present invention, the term "anti-inflammatory" refers to an action of suppressing inflammation, and the regulation of the inflammatory response is known to be very complex, which is known to enhance and reduce damage to the repair system in vivo. However, if the inflammatory response continues due to repeated tissue damage or regeneration, ROS and RNS are excessively produced in inflammation-related cells, resulting in permanent genetic modification. As such, ROS and RNS are deeply related to the inflammatory response that regulates the actions of various cells in vivo. During the inflammatory process, large amounts of the proinflammatory cytokines, nitric oxide (NO) and prostaglandin E2 (PGE2) are released into inducible nitric oxide synthase (iNOS) and cyclooxygenase enzymes. (cyclooxygenase-2, COX-2).
본 발명의 일 실시예에서는, 구절초 잎줄기, 도라지, 귤피, 구절초 건화, 배, 페퍼민트, 및 레몬그라스 열수 추출물을 준비하여, 이의 항산화 효능을 확인하고(도 1), 피부세포 및 대식세포에서의 세포 독성을 확인하였으며(도 2), LPS에 의한 염증매개 유전자인 iNOS, COX-2, 및 IL-6의 발현 변화를 측정하여, 각 열수 추출물을 단독으로 처리할 경우 항염증 효능이 없음을 확인하였고(도 3), 구절초 잎줄기 열수 추출물과 귤피, 페퍼민트, 또는 레몬그라스 열수 추출물을 조합할 경우, 단독 처리 시에는 나타나지 않았던 항염증 효능이 있음을 확인하였다(도 4).In one embodiment of the present invention, by preparing a hot water extract of gujeolcho leaf stem, bellflower, tangerine peel, gujeolcho dried flower, pear, peppermint, and lemongrass, confirming their antioxidant efficacy (FIG. 1), in skin cells and macrophages Cytotoxicity was confirmed (FIG. 2), and expression changes of iNOS, COX-2, and IL-6, which are inflammatory mediator genes by LPS, were measured, and it was confirmed that there was no anti-inflammatory effect when each hot water extract was treated alone. (FIG. 3), it was confirmed that when the hot-water extract of gujeolcho leaf stem and tangerine peel, peppermint, or lemongrass hot-water extract were combined, there was an anti-inflammatory effect that was not shown when treated alone (FIG. 4).
이를 통해, 상기 시료들을 단독으로 처리할 경우에는 염증 억제 효능이 나타나지 않았기에, 쉽게 유추할 수 없는, 항염 효능을 갖는 신규한 추출물 조합을 확인하였다.Through this, when the samples were treated alone, the anti-inflammatory effect did not appear, so a novel extract combination having an anti-inflammatory effect that could not be easily inferred was confirmed.
본 발명의 다른 하나의 양태는, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 약학 조성물을 제공한다.Another aspect of the present invention, (i) gujeolcho extract; and (ii) an anti-inflammatory pharmaceutical composition comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract.
이때, 상기 용어 “추출물”, “유효성분”, 및 “항염증”은 상기에서 상술한 바와 같다.At this time, the terms "extract", "active ingredient", and "anti-inflammatory" are as described above.
본 발명에서의 용어, “약학 조성물”은 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 추가로 포함할 수 있는데, 상기 담체는 비자연적 담체(non-naturally occuring carrier)를 포함할 수 있다.As used herein, the term “pharmaceutical composition” may further include a pharmaceutically acceptable carrier, excipient, or diluent, and the carrier may include a non-naturally occurring carrier.
구체적으로, “약학적으로 허용가능한 담체”는 생물체를 자극하지 않고 본 발명 조성물의 피부과색소 침착성 질환 증상의 예방 또는 치료 활성 및 특성을 저해하지 않는 담체 또는 희석제를 말한다. 액상 용액으로 제제화되는 조성물에 있어서 허용되는 약학적 담체로는, 멸균, 및 생체에 적합한 것으로서, 식염수, 멸균수, 링거액, 완충 식염수, 알부민 주사용액, 덱스트로즈 용액, 말토 덱스트린 용액, 글리세롤, 에탄올 및 이들 성분 중 하나 이상의 성분을 혼합하여 사용할 수 있으며, 필요에 따라 항산화제, 완충액, 정균제 등 다른 통상의 첨가제를 첨가할 수 있다.Specifically, "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not stimulate living organisms and does not inhibit the activity and properties of preventing or treating dermatological hyperpigmentation disease symptoms of the composition of the present invention. In the composition formulated as a liquid solution, acceptable pharmaceutical carriers are sterile and biocompatible, and include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, and ethanol. And one or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added if necessary.
또한, 본 발명의 약학적으로 허용가능한 담체는 비자연적 담체를 포함할 수 있다.In addition, pharmaceutically acceptable carriers of the present invention may include non-natural carriers.
보다 구체적으로, 상기 약학적 조성물에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트, 폴리카프로락톤(polycaprolactone), 폴리락틱액시드(Poly Lactic Acid), 폴리-L-락틱액시드(poly-L-lactic acid), 광물유 등을 들 수 있다.More specifically, carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, and calcium phosphate. , calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, polycaprolactone, polylactic acid (Poly Lactic Acid), poly-L-lactic acid, mineral oil, and the like.
상기 약학적 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용될 수 있으며, 담체의 형태로는 각종 부정형의 담체, 마이크로 스피어, 나노파이버 등을 포함할 수 있다.The pharmaceutical compositions may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively, The form of the carrier may include various irregular carriers, microspheres, nanofibers, and the like.
제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.When formulated, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 추출물과 이의 분획물들에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘 카보네이트(calcium carbonate), 수크로스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스티레이트, 탈크 같은 윤활제들도 사용될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations contain at least one excipient such as starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium styrate and talc may also be used.
경구투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Liquid preparations for oral administration include suspensions, internal solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. have.
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다.Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, suppositories, and the like. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여될 수 있는데, 상기 용어, “약학적으로 유효한 양”은 의학적 치료 또는 예방에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료 또는 예방하기에 충분한 양을 의미하며, 유효 용량 수준은 질환의 중증도, 약물의 활성, 환자의 연령, 체중, 건강, 성별, 환자의 약물에 대한 민감도, 사용된 본 발명 조성물의 투여 시간, 투여 경로 및 배출 비율 치료기간, 사용된 본 발명의 조성물과 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학적 조성물은 단독으로 투여하거나 공지된 익상편 치료제와 병용하여 투여될 수 있다. 상기 요소를 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하다.The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount, the term "pharmaceutically effective amount" is sufficient to treat or prevent disease with a reasonable benefit / risk ratio applicable to medical treatment or prevention. It means the amount, and the effective dose level is the severity of the disease, the activity of the drug, the patient's age, weight, health, sex, the patient's sensitivity to the drug, the administration time of the composition of the present invention used, the route of administration and the excretion rate, the treatment period , It may be determined according to factors including drugs used in combination or simultaneous use with the composition of the present invention used, and other factors well known in the medical field. The pharmaceutical composition of the present invention may be administered alone or in combination with a known therapeutic agent for pterygium. It is important to administer the amount that can obtain the maximum effect with the minimum amount without side effects in consideration of all the above factors.
본 발명의 또 다른 하나의 양태는, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 식품 조성물을 제공한다.Another aspect of the present invention, (i) gujeolcho extract; and (ii) an anti-inflammatory food composition comprising an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract as an active ingredient.
이때, 상기 용어 “추출물”, “유효성분”, 및 “항염증”은 상기에서 상술한 바와 같다.At this time, the terms "extract", "active ingredient", and "anti-inflammatory" are as described above.
본 발명의 조성물을 식품 첨가물로 사용할 경우, 상기 화합물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용할 수 있고, 통상의 방법에 따라 적절하게 사용할 수 있다. 유효 성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있으며, 식품학적으로 허용 가능한식품 보조 첨가제를 추가로 포함할 수 있다. 본 발명의 조성물은 천연물 유래 화합물로부터 합성한 화합물을 유효성분으로 하므로 안정성 면에서 문제가 없기 때문에 혼합량에 큰 제한은 없다.When the composition of the present invention is used as a food additive, the compound may be added as it is or used together with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health, or therapeutic treatment), and may further include food additives acceptable in food science. Since the composition of the present invention uses a compound synthesized from a natural product-derived compound as an active ingredient, there is no problem in terms of stability, so there is no great limitation on the mixing amount.
본 발명에서의 용어, “식품 조성물”은 통상적인 의미의 식품을 모두 포함할 수 있으며, 기능성 식품, 건강기능식품 등 당업계에 알려진 용어와 혼용 가능하다.In the present invention, the term "food composition" may include all foods in a conventional sense, and may be used interchangeably with terms known in the art, such as functional foods and health functional foods.
본 발명의 조성물이 사용될 수 있는 식품의 종류에는 제한이 없다. 아울러 본 발명의 화합물을 활성성분으로 포함하는 조성물은 당업자의 선택에 따라 식품에 함유될 수 있는 적절한 기타 보조 성분과 공지의 첨가제를 혼합하여 제조할 수 있다. 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림 류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 본 발명에 따른 화합물을 일성분으로 하여 제조한 즙, 차, 젤리 및 주스 등에 첨가하여 제조할 수 있다.There are no restrictions on the types of foods in which the composition of the present invention can be used. In addition, a composition containing the compound of the present invention as an active ingredient may be prepared by mixing suitable other auxiliary ingredients that may be contained in foods and known additives according to the selection of those skilled in the art. Examples of foods that can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages, and There are vitamin complexes, etc., and it can be prepared by adding the compound according to the present invention to juice, tea, jelly, juice, etc. prepared as one component.
또한, 본 발명에 적용될 수 있는 식품에는 예컨대, 특수영양식품(예: 조제유류, 영,유아식 등), 식육가공품, 어육제품, 두부류, 묵류, 면류(예: 라면류, 국수류 등), 건강보조식품, 조미식품(예: 간장, 된장, 고추장, 혼합장 등), 소스류, 과자류(예:스낵류), 유가공품(예: 발효유, 치즈 등), 기타 가공식품, 김치, 절임식품(각종 김치류, 장아찌 등), 음료(예: 과실, 채소류 음료, 두유류, 발효음료류 등), 천연조미료(예, 라면스프 등) 등 모든 식품을 포함할 수 있다.In addition, foods that can be applied to the present invention include, for example, special nutritional foods (e.g., formula milk, infant, baby food, etc.), processed meat products, fish meat products, tofu, jelly, noodles (e.g., ramen, noodles, etc.), health supplement food , seasonings (eg soy sauce, soybean paste, gochujang, mixed paste, etc.), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.) ), beverages (eg fruit, vegetable drinks, soy milk, fermented beverages, etc.), and natural seasonings (eg, ramen soup, etc.).
본 발명에서의 용어, "건강기능식품"은 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 의미하며, '기능성'은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건 용도에 유용한 효과를 얻는 것을 의미한다. 한편, 건강식품은 일반식품에 비해 적극적인 건강유지나 증진 효과를 가지는 식품을 의미하고, 건강보조식품은 건강 보조 목적의 식품을 의미하는데, 경우에 따라, 건강기능식품, 건강식품, 건강보조식품의 용어는 혼용될 수 있다.In the present invention, the term "functional health food" refers to food manufactured and processed using raw materials or ingredients having useful functionalities for the human body according to the Act on Health Functional Foods No. 6727, and 'functional' means It means to control nutrients with respect to structure and function or to obtain useful effects for health purposes such as physiological action. On the other hand, health food refers to food that has an active health maintenance or promotion effect compared to general food, and health supplement food refers to food for the purpose of supplementing health. In some cases, the terms of health functional food, health food, and health supplement food can be mixed.
보다 구체적으로, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 가공된 의학, 의료효과가 높은 식품을 의미하는데, 상기 식품은 비만의 예방 또는 개선에 유용한 효과를 얻기 위하여 정제, 캡슐, 분말, 과립, 액상, 환 등의 다양한 형태로 제조될 수 있다.More specifically, it refers to foods with high medical and medical effects that are processed to efficiently display bioregulatory functions in addition to nutritional supply. The foods are tablets, capsules, powders, granules, It can be prepared in various forms such as liquid and pills.
본 발명의 식품 조성물은 식품학적으로 허용가능한 담체를 추가로 포함하는 것일 수 있다.The food composition of the present invention may further include a carrier acceptable in food science.
본 발명의 조성물을 첨가할 수 있는 식품의 종류에는 별다른 제한이 없으며, 예를 들어 각종 음료, 껌, 차, 비타민 복합제, 건강 보조 식품류 등이 있다. 상기 식품 조성물에는 비만의 예방 또는 개선 효과에 방해가 되지 않는 다른 성분을 추가할 수 있으며, 그 종류는 특별히 제한되지 않는다.The type of food to which the composition of the present invention can be added is not particularly limited, and for example, there are various beverages, chewing gum, tea, vitamin complexes, health supplements, and the like. Other ingredients that do not interfere with the effect of preventing or improving obesity may be added to the food composition, and the type is not particularly limited.
예를 들어, 통상의 식품과 같이 여러 가지 생약 추출물, 식품학적으로 허용가능한 식품보조첨가제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다.For example, it may contain various herbal extracts, food-acceptable food additives, or natural carbohydrates as additional ingredients, like conventional foods.
또한, 상기 조성물은 식품 조성물에 통상 사용되어 냄새, 맛, 시각 등을 향상시킬 수 있는 추가 성분을 포함할 수 있다. 예를 들어, 비타민 A, C, D, E, B1, B2, B6, B12, 니아신(niacin), 비오틴(biotin), 폴레이트(folate), 판토텐산(panthotenic acid) 등을 포함할 수 있다. 또한, 아연(Zn), 철(Fe), 칼슘(Ca), 크롬(Cr), 마그네슘(Mg), 망간(Mn), 구리(Cu) 등의 미네랄을 포함할 수 있다. 또한, 라이신, 트립토판, 시스테인, 발린 등의 아미노산을 포함할 수 있다. 또한, 방부제(소르빈산 칼륨, 벤조산나트륨, 살리실산, 데히드로초산나트륨 등), 살균제(표백분과 고도 표백분, 차아염소산나트륨 등), 산화방지제(부틸히드록시아니졸(BHA), 부틸히드록시톨류엔(BHT) 등), 착색제(타르색소 등), 발색제(아질산 나트륨, 아초산 나트륨 등), 표백제(아황산나트륨), 조미료(MSG 글루타민산나트륨 등), 감미료(둘신, 사이클레메이트, 사카린, 나트륨 등), 향료(바닐린, 락톤류 등), 팽창제(명반, D-주석산수소칼륨 등), 강화제, 유화제, 증점제(호료), 피막제, 검기초제, 거품억제제, 용제, 개량제 등의 식품 첨가물(food additives)을 첨가할 수 있다. 상기 첨가물은 식품의 종류에 따라 선별되고 적절한 양으로 사용된다.In addition, the composition may include additional ingredients that are commonly used in food compositions to improve odor, taste, and visual properties. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like may be included. In addition, minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), and copper (Cu) may be included. In addition, amino acids such as lysine, tryptophan, cysteine, and valine may be included. In addition, preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), disinfectants (bleaching powder, high bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisole (BHA), butylhydroxytoluene ( BHT), etc.), coloring agents (tar color, etc.), coloring agents (sodium nitrite, sodium nitrite, etc.), bleaching agents (sodium sulfite, etc.), seasonings (MSG sodium glutamate, etc.), sweeteners (dulcin, cyclemate, saccharin, sodium, etc.) Food additives such as flavoring agents (vanillin, lactones, etc.), expanding agents (alum, D-potassium hydrogen tartrate, etc.), strengthening agents, emulsifiers, thickeners (thickeners), coating agents, gum base agents, foam inhibitors, solvents, improvers, etc. ) can be added. The additive is selected according to the type of food and used in an appropriate amount.
본 발명의 건강기능식품 조성물이 음료의 형태로 사용될 경우에는 통상의 음료와 같이 여러 가지 감미제, 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 외에 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다.When the health functional food composition of the present invention is used in the form of a beverage, it may contain various sweeteners, flavoring agents, or natural carbohydrates as additional components, like conventional beverages. In addition to the above, the health functional food composition of the present invention contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, and glycerin. , alcohol, a carbonating agent used in carbonated beverages, and the like. In addition, it may contain fruit flesh for the manufacture of natural fruit juice, fruit juice beverages and vegetable beverages.
본 발명의 건강기능식품은 당업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조 시에는 당업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어날 수 있다.The health functional food of the present invention can be prepared by a method commonly used in the art, and can be prepared by adding raw materials and components commonly added in the art during the preparation. In addition, unlike general drugs, there is an advantage in that there is no side effect that may occur when taking a drug for a long time by using food as a raw material, and it can be excellent in portability.
본 발명의 또 다른 하나의 양태는, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 항염증용 화장료 조성물을 제공한다.Another aspect of the present invention, (i) gujeolcho extract; and (ii) an anti-inflammatory cosmetic composition comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract.
이때, 상기 용어 “추출물”, “유효성분”, 및 “항염증”은 상기에서 상술한 바와 같다.At this time, the terms "extract", "active ingredient", and "anti-inflammatory" are as described above.
본 발명에서의 용어, “화장료 조성물”은 일반적인 유화 제형 및 가용화 제형의 형태로 제조할 수 있다. 상기 유화 제형으로는 영양화장수, 크림, 에센스 등이 있으며, 상기 가용화 제형으로는 유연화장수 등이 있다. 적합한 제형은 이에 제한되지는 않으나, 예를 들어 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 바이온형의 소낭 분산제의 형태, 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태일 수 있다. 또한, 포말(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태일 수 있다.The term "cosmetic composition" in the present invention may be prepared in the form of a general emulsion formulation and solubilization formulation. The emulsified formulation includes nutrient lotion, cream, essence, and the like, and the solubilization formulation includes softening lotion and the like. Suitable formulations include, but are not limited to, for example solutions, gels, solid or pasteurized anhydrous products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microgranules or ionic forms (liposomes), bioforms. It may be in the form of a vesicular dispersion, cream, toner, lotion, powder, ointment, spray or conceal stick. It may also be in the form of a foam or an aerosol composition further containing a compressed propellant.
상기 화장료 조성물은 추가적으로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제, 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제, 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장료 조성물에 통상적으로 사용되는 임의의 다른 성분과 같은 통상적으로 사용되는 보조제를 함유할 수 있다.The cosmetic composition may additionally contain fatty substances, organic solvents, solubilizers, thickeners and gelling agents, softeners, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metals. Commonly used adjuvants such as sequestering agents, chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or any other ingredient commonly used in cosmetic compositions may contain.
본 발명의 또 다른 하나의 양태는, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 유효성분으로 포함하는 조성물의 항염증 용도를 제공한다.Another aspect of the present invention, (i) gujeolcho extract; and (ii) an anti-inflammatory composition comprising, as an active ingredient, an extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extracts.
이때, 상기 용어 “추출물”, “유효성분”, 및 “항염증”은 상기에서 상술한 바와 같다.At this time, the terms "extract", "active ingredient", and "anti-inflammatory" are as described above.
본 발명의 구절초, 페퍼민트, 레몬그라스, 귤피 추출물을 단독으로 처리할 경우에는 염증 억제 효능이 나타나지 않았으나, (i) 구절초 추출물; 및 (ii) 페퍼민트, 레몬그라스, 및 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 복합하여 처리할 경우, 염증 억제 효능이 나타난 것을 확인하였기에, 상기 추출물 조합은 항염증용 조성물로서 널리 활용될 수 있을 것이다.When the extracts of gujeolcho, peppermint, lemongrass, and tangerine peel of the present invention were treated alone, the anti-inflammatory effect was not shown, but (i) gujeolcho extract; And (ii) when one extract selected from the group consisting of peppermint, lemongrass, and tangerine peel extract was treated in combination, it was confirmed that the anti-inflammatory effect was exhibited, so that the extract combination can be widely used as an anti-inflammatory composition. There will be.
도 1은 구절초 잎줄기, 도라지, 귤피, 구절초 건화, 배, 페퍼민트, 및 레몬그라스 열수 추출물의 항산화 효능을 나타내는 그래프이다.
도 2A는 DPPH 및 ABTS 어세이를 통한 구절초 잎줄기, 도라지, 귤피, 구절초 건화, 배, 페퍼민트, 레몬그라스 및 생강 열수 추출물의 RAW 264.7 세포에서의 세포 독성을 나타내는 그래프이다.
도 2B는 DPPH 및 ABTS 어세이를 통한 구절초 잎줄기, 도라지, 귤피, 구절초 건화, 배, 페퍼민트, 레몬그라스 및 생강 열수 추출물의 HaCaT 세포에서의 세포 독성을 나타내는 그래프이다.
도 3은 염증매개 유전자 발현 측정을 통해 구절초 잎줄기, 도라지, 귤피, 구절초 건화, 배, 페퍼민트, 레몬그라스 및 생강 열수 추출물의 항염증 효능을 나타내는 사진이다.
도 4는 염증매개 유전자 발현 측정을 통해 구절초 잎줄기 열수 추출물과 귤피, 페퍼민트, 또는 레몬그라스 열수 추출물의 조합의 항염증 효능을 나타내는 사진이다.Figure 1 is a graph showing the antioxidant efficacy of gujeolcho leaf stem, bellflower, tangerine peel, gujeolcho dried flowers, pear, peppermint, and lemongrass hot water extracts.
Figure 2A is a graph showing the cytotoxicity in RAW 264.7 cells of gujeolcho leaf stem, bellflower, tangerine peel, gujeolcho dry flower, pear, peppermint, lemongrass and ginger hot water extracts through DPPH and ABTS assays.
Figure 2B is a graph showing the cytotoxicity in HaCaT cells of hot water extracts of Gujeolcho leaf stem, bellflower, tangerine peel, Gujeolcho dry flower, pear, peppermint, lemongrass and ginger through DPPH and ABTS assays.
Figure 3 is a photograph showing the anti-inflammatory efficacy of gujeolcho leaf stem, bellflower, tangerine peel, gujeolcho dry, pear, peppermint, lemongrass and ginger hot water extracts through the measurement of inflammatory mediator gene expression.
Figure 4 is a photograph showing the anti-inflammatory efficacy of a combination of gujeolcho leaf stem hot-water extract and tangerine peel, peppermint, or lemongrass hot-water extract through measurement of inflammatory mediator gene expression.
이하, 본 발명을 하기 실시예를 통하여 보다 상세하게 설명한다. 그러나 이들 실시예는 본 발명을 예시적으로 설명하기 위한 것으로 본 발명의 범위가 이들 실시예만으로 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through the following examples. However, these examples are intended to illustrate the present invention by way of example, and the scope of the present invention is not limited only to these examples.
실시예 1. 시료 준비Example 1. Sample preparation
도라지, 배, 생강, 귤피, 구절초 잎줄기(잎과 줄기), 구절초 건화, 페퍼민트, 및 레몬그라스 8종의 원물을 열수 추출하여 추출물을 확보한 뒤, 다시 물에 용해하여 다양한 농도의 시료를 준비하였다.Extracts were obtained by hot water extraction of 8 original materials of bellflower, pear, ginger, tangerine peel, gujeolcho leaf stem (leaves and stems), dried flowers of gujeolcho, peppermint, and lemongrass, and then dissolved in water to prepare samples of various concentrations. did
보다 구체적으로, 상기 원물을 분쇄한 뒤, 분쇄한 원물을 물에 넣어 121℃의 열수로 압력을 가하여 추출하여 준비하였다.More specifically, after pulverizing the raw material, the pulverized raw material was put into water and extracted by applying pressure with hot water at 121 ° C. to prepare it.
실시예 2. 시료별 항산화능 분석Example 2. Analysis of antioxidant activity by sample
상기에서 준비한 시료별 항산화능을 DPPH 및 ABTS 어세이를 통해 분석하였다. 구체적으로, DPPH 어세이는 보라색 화합물인 DPPH를 항산화 활성이 있는 물질과 반응하여 구조변화가 일어나면 520 nm에서 광흡수가 일어나지 않는 노란색을 띄게 되어, 이를 측정하여 라디칼 소거능을 확인하는 어세이이며, ABTS 어세이는 페놀성 화합물과 반응하여 양이온을 띄고, 색상의 변화가 나타나면, 이를 600 ~ 750 nm에서 측정하여 항산화 활성을 확인하는 어세이이다.The antioxidant capacity of each sample prepared above was analyzed through DPPH and ABTS assays. Specifically, the DPPH assay is an assay to confirm the radical scavenging ability by measuring the purple compound DPPH reacting with a substance having antioxidant activity to obtain a yellow color with no light absorption at 520 nm when a structural change occurs, ABTS The assay is an assay for confirming antioxidant activity by reacting with a phenolic compound to generate cations and, when a color change appears, by measuring it at 600 to 750 nm.
그 결과, 도 1에서 볼 수 있듯이, ABTS 어세이를 통해, 3 mg/mL에서 페퍼민트는 약 62.7%, 레몬그라스는 약 23%, 구절초 잎줄기는 약 23%의 라디컬 소거능을 확인하였다. 또한, DPPH 어세이를 통해, 3 mg/mL에서 페퍼민트는 약 60.4%, 레몬그라스는 약 43%, 구절초 잎줄기는 약 40%의 라디컬 소거능을 확인하였다.As a result, as can be seen in Figure 1, through the ABTS assay, at 3 mg / mL, peppermint was confirmed to have about 62.7%, lemongrass about 23%, and Gujeolcho leaf stem about 23% of radical scavenging activity. In addition, through the DPPH assay, at 3 mg / mL, peppermint was confirmed to have about 60.4%, lemongrass about 43%, and Gujeolcho leaf stem about 40% of radical scavenging ability.
이를 통해, 도라지, 배, 귤피, 구절초 잎줄기, 구절초 건화, 페퍼민트, 및 레몬그라스 추출물 중 페퍼민트, 레몬그라스, 및 구절초 잎줄기에서 뛰어난 항산화 활성을 가지는 것을 확인하였다.Through this, it was confirmed that the extracts of bellflower, pear, tangerine, gujeolcho leaf stem, gujeolcho dry flower, peppermint, and lemongrass extracts had excellent antioxidant activity in peppermint, lemongrass, and gujeolcho leaf stem.
실시예 3. 시료별 세포 독성 분석Example 3. Cytotoxicity analysis by sample
상기에서 준비한 도라지, 배, 생강, 귤피, 구절초 잎줄기, 구절초 건화, 페퍼민트, 및 레몬그라스 열수 추출물의 세포 독성을 확인하였다.The cytotoxicity of the hot water extracts of bellflower, pear, ginger, tangerine peel, gujeolcho leaf stem, gujeolcho dry flower, peppermint, and lemongrass prepared above was confirmed.
보다 구체적으로, 피부세포주인 HaCaT 세포와 마우스 대식세포주인 RAW 264.7 세포에 도라지, 배, 귤피, 구절초 잎줄기, 구절초 건화, 및 페퍼민트 열수 추출물을 1, 10, 100, 및 1000 ug/mL, 레몬그라스 열수 추출물을 1, 10, 100, 및 500ug/mL, 생강 열수 추출물을 1, 10, 100, 및 250 ug/mL 처리한 후, 24시간 뒤에 MTT 어세이를 진행하였다.More specifically, HaCaT cells, a skin cell line, and RAW 264.7 cells, a mouse macrophage cell line, were given 1, 10, 100, and 1000 ug/mL of hot water extracts of bellflower, pear, tangerine, gujeolcho leaf stem, gujeolcho dried flower, and peppermint, lemongrass After treatment with 1, 10, 100, and 500 ug/mL of hot water extract and 1, 10, 100, and 250 ug/mL of hot water extract of ginger, MTT assay was performed 24 hours later.
그 결과, 도 2에서 볼 수 있듯이, 마우스 대식세포인 RAW264.7 세포에서 생강 추출물을 250 ug/mL로 처리하였을 때, 20% 정도 약간의 세포 감소가 나타났지만, 이외의 추출물에서는 세포 독성이 나타나지 않는 것을 확인하였다.As a result, as can be seen in Figure 2, when the ginger extract was treated with 250 ug / mL of mouse macrophage RAW264.7 cells, a slight cell reduction of about 20% was observed, but cytotoxicity was not observed in other extracts. confirmed that it is not.
이를 통해, 도라지, 배, 생강, 귤피, 구절초 잎줄기, 구절초 건화, 페퍼민트, 및 레몬그라스 열수 추출물이 피부세포 및 대식세포에서 대체로 세포 독성을 띄지 않는 것을 확인하였다.Through this, it was confirmed that the hot water extracts of bellflower, pear, ginger, tangerine peel, gujeolcho leaf stem, gujeolcho dried flower, peppermint, and lemongrass were not generally cytotoxic to skin cells and macrophages.
실시예 4. 열수 추출물 시료 단독 처리 시 항염증 효능 분석Example 4. Analysis of anti-inflammatory efficacy when treating hot water extract samples alone
상기에서 준비한 열수 추출물 시료별 세포 항염증 효능을 확인하였다.The cell anti-inflammatory efficacy of each of the hot water extract samples prepared above was confirmed.
구체적으로, 세포로부터 RNA를 추출한 뒤, cDNA를 합성하고, PCR을 통해, 염증매개 유전자인 iNOS, COX-2, 및 IL-6의 발현 변화를 확인하였다.Specifically, RNA was extracted from the cells, cDNA was synthesized, and expression changes of iNOS, COX-2, and IL-6, which are inflammatory mediator genes, were confirmed through PCR.
그 결과, 도 3에서 볼 수 있듯이, 상기 모든 열수 추출물 시료를 단독으로 처리하였을 경우, LPS 처리에 의해 증가되는 iNOS, COX-2, 및 IL-6의 발현에 큰 변화를 확인할 수 없었다.As a result, as can be seen in FIG. 3 , when all the hot water extract samples were treated alone, no significant changes were observed in the expression of iNOS, COX-2, and IL-6, which were increased by LPS treatment.
이를 통해, 상기 열수 추출물 시료들의 단독 처리는 항염증 효능을 가지지 않는 것을 확인하였다.Through this, it was confirmed that the treatment of the hot water extract samples alone did not have an anti-inflammatory effect.
실시예 5. 열수 추출물 시료 조합에서의 항염증 효능 분석Example 5. Analysis of anti-inflammatory efficacy in hot water extract sample combinations
상기에서 준비한 열수 추출물 시료 조합을 통한 세포 항염증 효능을 확인하였다.Cellular anti-inflammatory efficacy was confirmed through the combination of hot water extract samples prepared above.
구체적으로, 구절초 잎줄기 추출물과 도라지, 귤피, 페퍼민트, 레몬그라스 열수 추출물을 각각 혼합한 복합 추출물을 다양한 농도로 처리하여, 염증매개 유전자인 iNOS, COX-2, 및 IL-6의 발현 변화를 RT-PCR을 통해 확인하였다.Specifically, by treating the complex extract, which is a mixture of Gujeolcho leaf stem extract and bellflower, tangerine peel, peppermint, and lemongrass hot water extracts, respectively, at various concentrations, the expression changes of iNOS, COX-2, and IL-6, which are inflammatory mediator genes, were RT -Confirmed through PCR.
보다 구체적으로, 구절초 잎줄기 추출물은 10 ug/mL을 처리하였고, 도라지, 귤피, 페퍼민트, 레몬그라스는 1, 10, 또는 100 ug/mL을 처리하였다. 이후, 염증 자극제인 LPS를 100 ng/ml로 처리하고 24시간 뒤, 세포로부터 RNA를 추출하여 cDNA를 합성한 후 확인하였다.More specifically, Gujeolcho leaf stem extract was treated with 10 ug / mL, and bellflower, tangerine peel, peppermint, and lemongrass were treated with 1, 10, or 100 ug / mL. Thereafter, LPS, an inflammatory stimulant, was treated with 100 ng/ml, and after 24 hours, RNA was extracted from the cells, and cDNA was synthesized and confirmed.
그 결과, 도 4에서 볼 수 있듯이, 구절초 잎줄기 단독 처리할 경우에는 LPS 처리에 의해 증가되는 iNOS, COX-2, 및 IL-6의 발현에 변화가 없었지만, 구절초 잎줄기 열수 추출물과 귤피 열수 추출물 10 ug/mL, 페퍼민트 열수 추출물 100 ug/mL, 레몬그라스 열수 추출물 100 ug/mL를 각각 조합하여 처리한 경우, 단독 처리에서는 나타나지 않았던 iNOS, COX-2, 및 IL-6의 발현 억제능이 있음을 확인하였다. 하지만 도라지 추출물을 같이 처리한 조건에서는 유전자 발현 억제가 나타나지 않았다(도 4).As a result, as can be seen in Figure 4, when the gujeolcho leaf stem was treated alone, there was no change in the expression of iNOS, COX-2, and IL-6, which were increased by LPS treatment, but the gujeolcho leaf stem hot water extract and tangerine peel hot water extract When 10 ug/mL, peppermint
이를 통해, 구절초 잎줄기, 귤피, 페퍼민트, 및 레몬그라스 열수 추출물을 단독으로 처리할 경우에는 항염증 효능이 나타나지 않았지만, 구절초 잎줄기 열수 추출물과 귤피, 페퍼민트, 또는 레몬그라스 열수 추출물을 각각 조합할 경우에 월등한 항염증 효능이 나타나는 것을 확인하였다.Through this, when the gujeolcho leaf stem, tangerine peel, peppermint, and lemongrass hot water extract were treated alone, no anti-inflammatory effect was shown, but when the gujeolcho leaf stem hot water extract and tangerine peel, peppermint, or lemongrass hot water extract were combined, respectively It was confirmed that the superior anti-inflammatory effect appeared.
다시 말해, 본 발명에서는 구절초 잎줄기 추출물과 페퍼민트, 레몬그라스, 또는 귤피 추출물로 구성되는 군에서 선택된 하나의 추출물을 복합하여 처리할 경우의 뛰어난 염증 억제 효능을 확인하였으며, 이는 구절초 잎줄기, 페퍼민트, 레몬그라스, 귤피 추출물을 단독으로 처리할 경우에는 염증 억제 효능이 없었기에, 쉽게 유추할 수 없는, 항염증 효능을 갖는 신규한 추출물 조합을 확인하였음에 이의 의의가 크다.In other words, in the present invention, it was confirmed that the excellent anti-inflammatory effect was confirmed when the extract of gujeolcho leaf stem and one extract selected from the group consisting of peppermint, lemongrass, or tangerine peel extract was combined and treated. When the lemongrass and tangerine peel extracts were treated alone, there was no anti-inflammatory effect, so it is significant that a novel extract combination having an anti-inflammatory effect that could not be easily inferred was identified.
이상의 설명으로부터, 본 발명이 속하는 기술분야의 당업자는 본 발명이 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다. 이와 관련하여, 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로 이해해야만 한다. 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허 청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.From the above description, those skilled in the art to which the present invention pertains will be able to understand that the present invention may be embodied in other specific forms without changing its technical spirit or essential features. In this regard, it should be understood that the embodiments described above are illustrative in all respects and not limiting. The scope of the present invention should be construed as including all changes or modifications derived from the meaning and scope of the claims to be described later and equivalent concepts rather than the detailed description above are included in the scope of the present invention.
Claims (7)
(i) Gujeolcho extract; and (ii) an anti-inflammatory composition comprising peppermint extract as an active ingredient.
The anti-inflammatory composition according to claim 1, wherein the extract is a hot water extract.
According to claim 1, wherein the gujeolcho extract is an anti-inflammatory composition of the leaf stem extract of gujeolcho.
According to claim 1, wherein the peppermint extract and gujeolcho extract and 5: 1 to 15: 1 that will be included in a ratio of 1, anti-inflammatory composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200129598A KR102465347B1 (en) | 2020-10-07 | 2020-10-07 | A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200129598A KR102465347B1 (en) | 2020-10-07 | 2020-10-07 | A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220046737A KR20220046737A (en) | 2022-04-15 |
| KR102465347B1 true KR102465347B1 (en) | 2022-11-14 |
Family
ID=81212076
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200129598A KR102465347B1 (en) | 2020-10-07 | 2020-10-07 | A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102465347B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101571323B1 (en) | 2015-05-12 | 2015-11-24 | 주식회사 셀랩 | Cosmetic compositions comprising extract of herbs |
| JP2016191673A (en) | 2015-03-31 | 2016-11-10 | 一丸ファルコス株式会社 | Method of evaluating or selecting anti-inflammatory agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070069625A (en) * | 2005-12-28 | 2007-07-03 | (주)아모레퍼시픽 | Cosmetic composition containing mentha piperita extract for reducing irritation in skin irritated by retinoid |
| KR20180111016A (en) * | 2017-03-31 | 2018-10-11 | 주식회사 하이솔 | Composition for preventing, improving, or treating dermatitis comprising oil or hydrosol from plant as effective component |
| KR20200101113A (en) * | 2019-02-19 | 2020-08-27 | 정읍시 | A composition for improving, preventing and treating dermatitis comprising Chrysanthemum zawadskii var extract |
-
2020
- 2020-10-07 KR KR1020200129598A patent/KR102465347B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016191673A (en) | 2015-03-31 | 2016-11-10 | 一丸ファルコス株式会社 | Method of evaluating or selecting anti-inflammatory agents |
| KR101571323B1 (en) | 2015-05-12 | 2015-11-24 | 주식회사 셀랩 | Cosmetic compositions comprising extract of herbs |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220046737A (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2005072684A1 (en) | Maca extract manufacturing method | |
| KR101276141B1 (en) | Seed extract of seabuckthorn and method for producing the same | |
| JP2005060334A (en) | Anti-obesity agent having lipase inhibiting activity and antioxidation activity | |
| KR101874462B1 (en) | Composition for preventing, ameliorating or treating atopic dermatitis comprising Schisandra chinensis leaf extract as effective component | |
| KR20110004603A (en) | Extracts from sophora japonica l. for treating or preventing menopausal complaints, skin-aging, or skin wrinkle | |
| KR20210014231A (en) | Composition for prevention or treatment of muscular disorders or improvement of muscular functions comprising seaweeds extract | |
| JP2022009308A (en) | Composition for ameliorating climacteric symptoms or osteoporosis | |
| WO2005094860A1 (en) | Agent improving peripheral blood flow | |
| JP5309292B2 (en) | Lipase inhibitor | |
| KR102228257B1 (en) | Composition for anti-inflammation or anti-acne comprising extract of Immature Citrus Fruit, Curcuma longa and citrus blossom honey | |
| KR102179610B1 (en) | Composition for preventing hair loss or promoting hair growth containing essential oil mixture of Coicis semen and Evening Primrose seeds | |
| KR102465346B1 (en) | A composition comprising Chrysanthemum zawadskii and Cudrania tricuspidata Bureau having anti-inflammation activity | |
| JP2003055244A (en) | Agent promoting hyaluronic acid production, cosmetics, food and beverage including the hyaluronic acid production-promoting agent | |
| KR102613550B1 (en) | A ginsenoside complex comprising insoluble substance curcumin | |
| KR102465347B1 (en) | A composition for anti-inflammation activity comprising Chrysanthemum zawadskii leaf and stem | |
| KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR101863117B1 (en) | Composition comprising Androsace umbellate extract, Vaccinium oldhami extract, and Deutzia crenata extract | |
| KR102315700B1 (en) | Composition for treating or preventing acne comprising elaeagnus umbellata leaves extract | |
| KR20170122501A (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| KR20220099175A (en) | Oral composition comprising herbal complex | |
| KR101889492B1 (en) | composition containing complex extract of Morus alba for pendula, Prunus salicina and Oenothera lamarckiana | |
| KR102347819B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR20190062021A (en) | Cosmetic composition comprising grape vinegar starter and fermented herb extract and preparing method of the same | |
| EP3449736B1 (en) | Composition for relieving menopausal symptom or osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |